Twilight Litaka Pharma Limited
Regd. Office : Himalaya Estate, 16-A Shivajinagar, Pune 411 005

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2010

(Rs.in Lac)

S No.	Particulars	Quarter Ended (Unaudited)		Nine months Ended (Unaudited)		Financial Year Ended (Audited)
		31.12.2010	31.12.2009	31.12.2010	31.12.2009	31.03.2010
1	a. Net Sales / Income From Operations	17215.24	12787.26	49502.92	35311.78	49196.22
	b. Other Operating Income	-	-	-	-	-
2	Expenditure					
	a Increase/decrease in stock in trade & WIP	-49.34	16.03	-704.89	-455.38	-1006.72
	b Consumption of Raw material	12055.98	9374.38	35295.70	26177.43	35194.61
	c Purchase of traded goods.	1210.17	734.87	3559.38	1909.35	3691.29
	d Employee cost	468.01	348.85	1320.17	1078.72	1601.21
	e Depreciation	95.69	69.72	272.98	217.87	305.45
	f Other expenditure	949.64	752.60	2749.07	2189.52	3472.38
	g Expenditure (a to f)	14730.15	11296.45	42492.41	31117.51	43258.22
3	**Profit from Operations before Other Income, Interest and Exceptional Items (1-2)**	2485.09	1490.81	7010.51	4194.27	5938.00
4	Other Income	67.37	53.51	169.97	125.54	267.92
5	**Profit before Interest & Exceptional Items (3+4)**	2552.46	1544.32	7180.48	4319.81	6205.92
6	Interest	814.48	484.90	2058.29	1469.62	2150.75
7	**Profit after Interest, but before Exceptional Items (5-6)**	1737.98	1059.42	5122.19	2850.19	4055.17
8	Exceptional Items	-	-	-	-	-
9	**Profit from Ordinary Activities before tax (7+8)**	1737.98	1059.42	5122.19	2850.19	4055.17
10	Tax Expenses	376.00	187.00	1081.00	459.00	792.65
11	**Profit from Ordinary Activities after tax (9-10)**	1361.98	872.42	4041.19	2391.19	3262.52
12	Extraordinary items (net of tax expense)	-	-	-	-	-
13	**Net Profit for the period**	1361.98	872.42	4041.19	2391.19	3262.52
14	Paid-up Equity Share Capital (Equity share of Rs.5/- each)	1064.06	1064.06	1064.06	1064.06	1064.06
15	Reserve excluding revaluation reserves	12264.31	7694.02	12264.31	7694.02	8223.13
16	Earning per share (EPS)					
	a. Basic and diluted EPS before extraordinary items for the period	*6.40	*4.10	*18.99	*11.24	15.33
	b. Basic and diluted EPS after extraordinary items for the period.	*6.40	*4.10	*18.99	*11.24	15.33
17	Aggregate of non promoter shareholding					
	number of shares	12343051	7716036	12343051	7716036	7767036
	percentage of shareholding	58.00	36.26	58.00	36.26	36.50
18	Promoters and Promoters Group shareholding					
	a) Pledged / Encumbered					
	- Number of shares	8541025	5781588	8541025	5781588	5781588
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	95.56	42.62	95.56	42.62	42.62
	- Percentage of shares (as % to the total share capital of the Company)	40.13	27.17	40.13	27.17	27.17
	b) Non Encumbered					
	- Number of shares	397209	7783661	397209	7783661	7732661
	- Percentage of shares (as % to the total shareholding of promoters & promoters group)	4.44	57.38	4.44	57.38	57.38
	- Percentage of shares (as % to the total share capital of the Company)	1.87	36.57	1.87	36.57	36.57

* not annulised

Notes :

1] The above unaudited results were reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on 12th February, 2011.

2] Provision for Tax includes Current Year Tax and Deferred Tax

3] The Company is primarily engaged in Pharmaceutical formulations business, which in the context of Accounting Standard (AS17) "Segment Reporting" is considered to be the only business segment.

4] On 13th March,2010 Company has allotted 35,00,000 Convertible Warrants at Rs. 86/- each to the applicants as per terms of issue. These warrants are convertible into Equity Shares of the Company within a period of 18 months from the date of their allotment at the option of warrants holders.

5] The Company has entered into "Share Purchase Agreement" with Briocia Pharma (India) Pvt Ltd on 28th April,10 . As per the said Agreement, Briocia Pharma (India) Pvt. Ltd., has become 100% subsidiary of the Company w.e.f. 25.11.2010. The Financial results for the period ended December 31, 2010 of the Company are prepared on standalone basis.

6] The Statutory Auditors of the Company have carried out the Limited Review of the above results.

7] Previous year's figures have been regrouped and rearranged wherever necessary.

8] During the current quarter, ten investor complaint were received. There was no pending investor complaint at the beginning of the quarter and at the end of the quarter.

For TWILIGHT LITAKA PHARMA LIMITED

GOPAL RAMOURTI
Managing Director

TWILIGHT LITAKA PHARMA LTD. PUNE

Place : Pune
Date : 12th February, 2011